Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taxol/cisplatin three-hour therapy causes higher rate of peripheral neuropathy -- Gynecologic Oncology.

Executive Summary

TAXOL/CISPLATIN THREE-HOUR COMBO THERAPY INCREASES PERIPHERAL NERVE DAMAGE incidence compared to the regimen given over 24 hours, according to results of a study published in the August issue of Gynecologic Oncology. The 38-patient study was conducted at the Cleveland Clinic Cancer Center in Ohio and involved 20 ovarian, six primary peritoneal and 12 endometrial malignancy patients who were administered 170 cycles of 135 mg/m2 or 175 mg/m2 paclitaxel (Bristol-Myers Squibb's Taxol) over three hours immediately followed by 75 mg/m2 cisplatin delivered over 30 minutes.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS028694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel